May 9, 2019 7:27am

Thursday’s Q1 reporting includes:  Ionis Pharmaceuticals (IONS), Caladrius Biosciences (CLBS), Intrexon (XON) and BioTime (NYSEMKT: BTX)

Pre-open indications: 4 BUYs and 2 SELLs

The 6 W’s: Who, what, where, when, why and what of it … the real question is who is going to report what?  Should have been a reader … you would understand a little more of what to do in a crazy market!


Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.


Dow futures are DOWN -0.63% (-163 points), S&P futures are DOWN -0.65% (-19 points) and NASDAQ futures are DOWN -0.83% (-64 points)


US futures point to a lower open as trade tensions continue;

European markets slide as trade fears mount with the pan-European STOXX 600 was down 0.8% in mid-morning trade, while the CAC 40 traded 1.3% lower;

Asia markets slip as Trump claims China 'broke the deal' in trade talks;


Data docket: international trade figures, weekly jobless claims, and producer price index numbers out at 8.30 a.m. ET.



U.S. stock index futures were lower on Thursday morning, as market participants continued to monitor trade relations between the U.S. and China.

Today is a good to play shuffle board share pricing; it’s about buying or selling into the edges but, not over!


From Wednesday’s closing bell post, “headlines drive volatile momentum with Q1/19 earnings in the second seat yet, my coverage (45) list’s Advance/Decline (A/D) line closed positive 24/18, 1 flat and 2 acquired; as I had stated, “Post reporting Q1/19, many companies lost blood yet, the oversold band aid will soon stem the pricing decline flow.”

Last evening:

  • Wednesday’s range of the 24 upside was +0.12% (ONCE) to +4.74% (XON) while the 18 downside ranged from -0.09% (SGMO) to -21.09% (ADRO);
  • Wednesday: 4 out of the 24 upside had higher than the 3 month average volume;
  • Wednesday: 8 out of the 18 downside had higher than the 3 month average volume;

Q2/19 so far:

  • In May, there were 3 negative and 3 positive closes;
  • In April, there has been 10 positive and 11 negative closes;


Companies in my headlights – It’s your decision; I provide an idea and context:

  • Thursday’s Q1 reporting includes:  Ionis Pharmaceuticals (IONS), Caladrius Biosciences (CLBS), Intrexon, and BioTime (NYSEMKT: BTX)


bluebird bio (BLUE) closed down -$4.53 after Tuesday’s -$10.29 and Monday’s +$3.99 – Oversold, BUY;


Post earnings release:

Adverum Biotechnologies (ADVM) closed down -$0.37) after exceeding expectation – BUY;

AxoGen (AXGN) closed down -$1.42, a Q1 loss, tops revenue estimates and is exhibiting a positive +$1.25 or +5.43% - BUY;

Global Blood Therapeutics (GBT) closed up +$2.46, surpassing “street” expectations – BUY;

Athersys (ATHX) closed down -$0.03 and has a negative -$0.05 or -3.18% aftermarket indication – SELL;

Sangamo Therapeutics (SGMO) closed down -$0.01, missed expectation and has a negative -$0.51 or -4.51% aftermarket indication – SELL;


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.